Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Learn more about:
Related Clinical Trial
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer Impact of Margin-accentuation IRE in Pancreatic Cancer Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer Diet and Exercise After Pancreatic Cancer Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery Gem-TABS in Unresectable Pancreatic Carcinoma Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer Safety and Efficacy Study of Five-fraction Stereotactic Body Radiation Therapy to Locally Advanced Pancreatic Cancer Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer A Study of ABTL0812 in Pancreatic Cancer Immune Response After Pancreatic Cancer Treatment Combination of Stereotactic Body Radiation Therapy With S-1 for Treating Locally Advanced Pancreatic Cancer Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer New Treatment Option for Pancreatic Cancer Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer Usefulness of Smartphone Application for Improving Nutritional Status of Pancreatic Cancer Patients Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer C-VISA BikDD: Liposome in Advanced Pancreatic Cancer Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer QUILT-3.080: NANT Pancreatic Cancer Vaccine Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer Oral Microbiome and Pancreatic Cancer IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer Impact of Three-dimensional Visualization on Operation Strategy and Complications for Pancreatic Cancer A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer. BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer A Real-world Study of Albumin-bound Paclitaxel in the Treatment of Pancreatic Cancer Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Dasatinib in Treating Patients With Stage IV Pancreatic Cancer Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer Ghrelin Levels in Pancreatic Cancer Patients Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer A Phase II Study of Locally Advanced Pancreatic Cancer QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer Study of Ruxolitinib in Pancreatic Cancer Patients Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Study of CellCept for Advanced Pancreatic Cancer Niraparib in Patients With Pancreatic Cancer Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer Longitudinal Pancreatic Cancer Study Safety and Efficiency of γδ T Cell Against Pancreatic Cancer A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer Autologous CARTmeso/19 Against Pancreatic Cancer Clinical Application of IRE Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer Depression, Cytokines and Pancreatic Cancer Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer Identification of Biomarkers for Early Detection of Pancreatic Cancer Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer Nano Drug Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Carcinoma Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Gene Expression in Pancreatic Cancer Optical and Biochemical Biomarkers in Early Pancreatic Cancer Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer Valproic Acid With Chemoradiotherapy for Pancreatic Cancer Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer A Trial of Chemo & Radiation Therapy for Pancreatic Cancer Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Vaccine Treatment for Surgically Resected Pancreatic Cancer Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice Quality of Life After Radiofrequency Ablation of Pancreatic Cancer Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC) Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Pancreatic Cancer Collaborative Registry Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer Focused Ultrasound for the Treatment of Pancreatic Cancer – an International Registry Registry for Pancreatic Cancer Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer GI-4000 With Adoptive Transfer in Pancreatic Cancer Pancreatic Cancer Genetic Epidemiology (PACGENE) Study Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer Clinical Trial of Pancreatic Cancer in Stockholm. Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer Acquisition of Portal Venous CTCs and Exosomes From Patients With Pancreatic Cancer by EUS Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas Stool Testing for Pancreatic Cancer A Phase III Study of Pancreatic Cancer Pancreatic Cancer Genetics Integrated Positron Emission Tomography – Computed Tomography (PET-CT) in Patients With Pancreatic Cancer RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer Vaccine Study for Surgically Resected Pancreatic Cancer Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer Studying Biomarkers in Patients With Pancreatic Cancer Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.

Brief Title

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Official Title

Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Brief Summary

      A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic
      body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine
      the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the
      treatment of locally advanced pancreatic cancer. Investigators will also estimate the
      surgical resection rate following treatment with combined cabiralizumab, nivolumab and
      radiotherapy in subjects with locally advanced unresectable pancreatic cancer.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Measure of safety of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer measured by unacceptable toxicity


Condition

Pancreatic Cancer

Intervention

Nivolumab + Cabiralizumab

Study Arms / Comparison Groups

 Multi Agent Chemotherapy Cancer Patients
Description:  Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

20

Start Date

July 31, 2018

Completion Date

July 20, 2020

Primary Completion Date

July 20, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed locally advanced, unresectable pancreatic cancer as defined
             by NCCN Guidelines 3.2017

          -  Locally advanced unresectable disease is defined by the NCCN as:

          -  Tumors of the head that have greater than 180 degrees of SMA encasement or any celiac
             abutment, unreconstructable SMV or portal occlusion, or aortic invasion or encasement.

          -  Tumors of the body with SMA or celiac encasement of greater than 180 degrees,
             unreconstructable SMV or portal occlusion, or aortic invasion.

          -  Tumors of the tail with SMA or celiac encasement of greater than 180 degrees.
             Irrespective of location, all tumors with evidence of nodal metastasis outside of the
             resection field are deemed unresectable.

          -  Patients must agree to pretreatment and on treatment tumor biopsy

          -  ECOG performance status of 0 or 1

          -  Completion of at least 2 months, but no more than 6 months of standard induction
             chemotherapy for LAPC, which must include either FOLFIRINOX or gemcitabine and nab-
             paclitaxel, preferably within 2-4 weeks but no longer than 8 weeks.

          -  Normal organ and marrow function as defined below:

          -  absolute neutrophil count ≥ 1,500/mm3

          -  platelets ≥ 100,000/mm3

          -  total bilirubin ≤ 1.5 x institutional upper limit of normal (except participants with
             Gilbert's syndrome who must have normal direct bilirubin)

          -  AST(SGOT) and ALT(SGPT) ≤ 2 × institutional upper limit of normal

          -  creatinine ≤ 1.5 mg/ dL OR

          -  creatinine clearance≥ 30 mL/min (as estimated by Cockcroft Gault Equation)

          -  Ability to understand and sign a written informed consent document. Participant must
             have willingness and ability to comply with scheduled visits, treatment plans,
             laboratory tests and other study procedures.

          -  Women of childbrearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study treatment.

          -  WOCBP must agree to follow instructions for method(s) of contraception for the
             duration of treatment with study treatment(s) and for a total of 5 months
             post-treatment completion.

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception (see appendix 1) for the duration of treatment with study
             treatment(s) and for a total of 7 months posttreatment completion. In addition, male
             participants must be willing to refrain from sperm donation during this time.

        Exclusion Criteria:

          -  Resectable, borderline resectable or metastatic disease

          -  Interstitial lung disease that is symptomatic or may interfere with the detection or
             management of suspected treatment-related pulmonary toxicity.

          -  Participants with a condition requiring systemic treatment with either corticosteroids
             (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within
             14 days of study treatment administration except for adrenal replacement steroid doses
             > 10 mg daily prednisone equivalent in the absence of active autoimmune disease.

        Note: Treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating
        study treatment is permitted.

          -  Current or history of clinically significant muscle disorders (eg, myositis), recent
             unresolved muscle injury, or any condition known to elevate serum CK levels

          -  Uncontrolled or significant cardiovascular disease including, but not limited to, any
             of the following:

          -  Myocardial infarction or stroke/transient ischemic attack within the past 6 months

          -  Uncontrolled angina within the past 3 months

          -  Any history of clinically significant arrhythmias (such as ventricular tachycardia,
             ventricular fibrillation, or torsades de pointes)

          -  History of other clinically significant heart disease (eg, cardiomyopathy, congestive
             heart failure with New York Heart Association functional classification III to IV,
             pericarditis, significant pericardial effusion, or myocarditis)

          -  Cardiovascular disease-related requirement for daily supplemental oxygen therapy.

          -  Evidence of uncontrolled, active infection, requiring parenteral anti-bacterial,
             anti-viral or anti-fungal therapy ≤ 7 days prior to administration of study
             medication.

          -  Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative
             colitis.

          -  Participants with active, known, or suspected autoimmune disease. Participants with
             vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune
             condition only requiring hormone replacement, euthyroid participants with a history of
             Grave's disease (participants with suspected autoimmune thyroid disorders must be
             negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating
             immunoglobulin prior to first dose of study treatment), psoriasis not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger are permitted to enroll after discussing with the Principal Investigator.

          -  Concomitant use of statins while on study. However, a patient using statins for over 3
             months prior to study drug administration and in stable status without CK rise may be
             permitted to enroll.

          -  Non-oncology vaccine therapies for prevention of infectious diseases (eg, human
             papillomay virus vaccine) within 4 weeks of study drug administration. The inactivated
             seasonal influenza vaccine can be given to patients before treatment and while on
             therapy without restriction. Influenza vaccines containing live virus or other
             clinically indicated vaccinations for infectious diseases (ie, pneumovax, varicella,
             etc) may be permitted, but must be discussed with the principal investigator and may
             require a study drug washout period prior to and after administration of vaccine.

          -  Known human immunodeficiency virus (HIV), known active hepatitis A, or known hepatitis
             B or C infection.

          -  History of acute diverticulitis within the last 6 months, or current chronic diarrhea

          -  Pregnant or lactating women.

          -  Women of childbearing potential (WOCBP) with either a positive or no pregnancy test
             (serum or urine) at baseline. (Postmenopausal women must have been amenorrheic for at
             least 12 months to be considered of non-childbearing potential.)

          -  WOCBP who are unwilling or unable to use an acceptable method to minimize the risk of
             pregnancy (see appendix 1) for the entire study period and for at least 5 months after
             the last dose of investigational product. WOCBP who are continuously not
             heterosexually active are also exempt from contraceptive requirements, but still must
             undergo pregnancy testing as described in section - Sexually active fertile men not
             using effective birth control if their partners are WOCBP

          -  History of primary immunodeficiency.

          -  History of organ allograft or allogeneic bone marrow transplant.

          -  Any prior radiation therapy, immunotherapy, or biologic ('targeted') therapy for
             treatment of the patient's pancreatic tumor. Patient should have received either
             FOLFIRINOX or gemcitabine and nab-paclitaxel prior to enrollment.

          -  Treatment for other invasive carcinomas within the last five years who are at greater
             than 5% risk of recurrence at time of eligibility screening. Carcinoma in-situ and
             basal cell carcinoma/ squamous cell carcinoma of the skin are allowed.

          -  Participation in any investigational drug study within 4 weeks preceding the start of
             study treatment.

          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,
             without complete recovery.

          -  History of allergy to study treatments or any of its components

          -  Known history of sensitivity to infusions containing Tween 20 (polysorbate 20) and
             Tween 80 (polysorbate 80)
      

Gender

All

Ages

18 Years - 100 Years

Accepts Healthy Volunteers

No

Contacts

Deirdre Cohen, MD, 212 731 5656, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03599362

Organization ID

17-01430


Responsible Party

Sponsor

Study Sponsor

NYU Langone Health


Study Sponsor

Deirdre Cohen, MD, Principal Investigator, NYU Langone Health


Verification Date

November 2019